Search

Viatris Inc

Chiusa

SettoreSettore sanitario

20.83 0.73

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

20.73

Massimo

20.86

Metriche Chiave

By Trading Economics

Entrata

-207M

-325M

Vendite

-7.3M

3.7B

EPS

0.71

Rendimento da dividendi

2.41

Margine di Profitto

-8.676

Dipendenti

30,000

EBITDA

209M

938M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+0.86% upside

Dividendi

By Acuity

Rendimento da dividendi

Media del settore

2.41%

1.98%

Prossima data del Dividendo

16 dic 2026

Prossima data del' Ex Dividendo

23 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

2B

23B

Apertura precedente

20.1

Chiusura precedente

20.83

Viatris Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

13 nov 2026, 20:46 UTC

Viatris Inc. is trading higher, having fluctuated earlier in the session, and is positioned above its 20-day moving average near the upper end of its one-month range.

12 nov 2026, 23:11 UTC

Viatris Inc. is trading higher in after-market hours, reaching its highest point of the day and positioned above its 20-day moving average.

11 nov 2026, 21:06 UTC

News

Viatris Inc. will participate in three upcoming investor conferences, including the UBS Global Biopharma Conference on November 17.

9 nov 2026, 21:04 UTC

Viatris Inc. is moving higher, supported by rising U.S. wholesale inventories and cautious optimism from Federal Reserve officials ahead of key inflation data.

7 nov 2026, 00:01 UTC

Viatris Inc. is trading lower in after-market hours, showing a slight decline while remaining above its 20-day moving average and near the upper end of its one-month range.

6 nov 2026, 23:01 UTC

In after-market trading, Viatris Inc. is roughly flat compared to Friday's close, remaining above its 20-day moving average and near the upper end of its one-month range.

5 nov 2026, 21:04 UTC

News

Viatris reports Q3 adjusted EPS of $0.71, exceeding estimates, but posts a net loss of $325.3 million and revenue of $3.75 billion, below expectations.

4 nov 2026, 22:02 UTC

Viatris Inc. is trading higher in after-market hours, advancing alongside the broader market and remaining well above its 20-day moving average.

3 nov 2026, 22:02 UTC

Viatris Inc. shares declined in after-market trading, remaining stable above their 20-day moving average and near the upper end of their one-month range.

2 nov 2026, 21:09 UTC

Viatris Inc. shares fell as the broader market declined, dropping from an initial gain to the day's lowest point since Friday's close.

30 ott 2026, 19:36 UTC

News

Viatris initiates cash tender offer to acquire Pacira BioSciences at $36.50 per share, with unanimous board support; offer expires November 16, 2026.

29 ott 2026, 23:41 UTC

Viatris Inc. is declining in after-market trading, having retraced from a peak earlier in the session and nearing its lowest point of the day.

28 ott 2026, 20:07 UTC

Viatris Inc. shares advanced, reaching a peak reflecting nearly 1% cumulative return earlier in the session, while overall trading activity remained routine.

27 ott 2026, 22:41 UTC

Viatris Inc. is trading modestly lower in after-market hours, having retraced from a brief high earlier in the session.

26 ott 2026, 20:06 UTC

News

Piper Sandler raises price target on Viatris Inc to $14.00 from $13.00 while maintaining a Neutral rating, published today at 8:02 AM ET.

23 ott 2026, 20:13 UTC

Viatris Inc. is trading modestly higher in after-market hours, maintaining a steady position above its 20-day moving average since Friday's close.

21 ott 2026, 19:36 UTC

News

JPMorgan raises Viatris price target to $20.00 from $18.00 while maintaining a Neutral rating, amid cautious sentiment contributing to today's decline.

20 ott 2026, 20:51 UTC

Viatris Inc shares fell during after-market trading, continuing a downward trend since Tuesday's close despite a brief recovery earlier in the session.

19 ott 2026, 20:13 UTC

Viatris Inc. shares advanced modestly during after-market hours, maintaining a cumulative return since the close of regular trading and positioned above its 20-day moving average.

16 ott 2026, 23:01 UTC

News

Viatris receives FDA approval for Ryzumvi to treat presbyopia in adults and seeks U.S. partners for commercialization under a licensing agreement with Opus Genetics.

15 ott 2026, 20:02 UTC

News

Barclays issues a bullish outlook on Viatris, citing a positive setup for Q3 and optimism for fiscal year 2027.

14 ott 2026, 20:07 UTC

Viatris Inc shares are advancing, building on gains since Tuesday, despite pulling back from an earlier session high. The stock is trading around its one-month range midpoint.

13 ott 2026, 19:36 UTC

Viatris Inc shares fell, continuing a downward trend that began after Monday's close, despite an initial peak in early trading.

12 ott 2026, 20:06 UTC

Viatris Inc shares fell modestly, reflecting a broader market trend, while fluctuating around the midpoint of their one-month range.

9 ott 2026, 23:50 UTC

In after-market trading, Viatris Inc shares advanced, reflecting upward momentum and reaching a high cumulative return since Friday's close.

8 ott 2026, 20:13 UTC

Event

Viatris Inc announces acquisition of Pacira BioSciences for $1.65 billion, including all remaining shares not tendered in the initial offer.

7 ott 2026, 20:08 UTC

Social Media

Viatris Inc shares are declining as the FDA review of its MR-141 drug approaches on October 17, despite earlier gains in the session.

6 ott 2026, 20:06 UTC

Viatris Inc shares fell modestly, retracing after an initial rise and closing below Monday's close, while remaining above the 20-day moving average.

5 ott 2026, 20:06 UTC

Viatris Inc's shares are trading roughly flat, with little change since Friday's close, remaining around the middle of its one-month trading range.

2 ott 2026, 23:45 UTC

Viatris Inc declined in after-market hours, continuing a trend of lower prices observed over the past four sessions since Friday's close.

Confronto tra pari

Modifica del prezzo

Viatris Inc Previsione

Obiettivo di Prezzo

By TipRanks

0.86% in crescita

Previsioni per 12 mesi

Media 21 USD  0.86%

Alto 28 USD

Basso 14 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Viatris Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

9 ratings

5

Acquista

3

Mantieni

1

Vendi

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Viatris Inc

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
help-icon Live chat